These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 17576547)

  • 1. Triptan use and risk of cardiovascular events: a nested-case-control study from the French health system database.
    Lugardon S; Roussel H; Sciortino V; Montastruc JL; Lapeyre-Mestre M
    Eur J Clin Pharmacol; 2007 Aug; 63(8):801-7. PubMed ID: 17576547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triptans use and overuse: A pharmacoepidemiology study from the French health insurance system database covering 4.1 million people.
    Braunstein D; Donnet A; Pradel V; Sciortino V; Allaria-Lapierre V; Lantéri-Minet M; Micallef J
    Cephalalgia; 2015 Nov; 35(13):1172-80. PubMed ID: 25667299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential Channeling Bias in the Evaluation of Cardiovascular Risk: The Importance of Comparator Selection in Observational Research.
    Li H; Mawanda F; Mitchell L; Zhang X; Goodloe R; Vincent M; Motsko S
    Pharmaceut Med; 2022 Aug; 36(4):247-259. PubMed ID: 35788962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triptans and vascular comorbidity in persons over fifty: Findings from a nationwide insurance database - A cohort study.
    Zebenholzer K; Gall W; Gleiss A; Pavelic AR; Wöber C
    Headache; 2022 May; 62(5):604-612. PubMed ID: 35593784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Patterns of prescription and usage of triptans in Alsace (France): misuse is frequent and avoidable].
    Perearnau P; Vuillemet F; Schick J; Weill G
    Rev Neurol (Paris); 2006 Mar; 162(3):347-57. PubMed ID: 16585890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triptans in migraine: the risks of stroke, cardiovascular disease, and death in practice.
    Hall GC; Brown MM; Mo J; MacRae KD
    Neurology; 2004 Feb; 62(4):563-8. PubMed ID: 14981171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use and overuse of triptans in Austria - a survey based on nationwide healthcare claims data.
    Zebenholzer K; Gall W; Wöber C
    J Headache Pain; 2018 May; 19(1):34. PubMed ID: 29777424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine: systematic review of observational studies.
    Roberto G; Raschi E; Piccinni C; Conti V; Vignatelli L; D'Alessandro R; De Ponti F; Poluzzi E
    Cephalalgia; 2015 Feb; 35(2):118-31. PubMed ID: 25246519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of Stroke and Myocardial Infarction Among Initiators of Triptans.
    Petersen CL; Hougaard A; Gaist D; Hallas J
    JAMA Neurol; 2024 Mar; 81(3):248-254. PubMed ID: 38315477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utilization patterns, cardiovascular risk, and concomitant serotoninergic medications among triptan users between 2008 and 2018: A gender analysis in one Italian region, Tuscany.
    Hyeraci G; Gini R; Bezin J; Iannone LF; Benemei S; Lupi C; De Cesaris F; Geppetti P; Roberto G
    Headache; 2023 Feb; 63(2):222-232. PubMed ID: 36705316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Migraine burden and costs in France: a nationwide claims database analysis of triptan users.
    Donnet A; Emery C; Aly S; Allaf B; Cayre F; Mahieu N; Gourmelen J; Levy P; Fagnani F
    J Med Econ; 2019 Jul; 22(7):616-624. PubMed ID: 30836035
    [No Abstract]   [Full Text] [Related]  

  • 12. Trends in Triptan Usage in Korea: A Population-Based Cohort Study.
    Ha WS; Jeong J; Song S; Yum J; Chu MK
    J Korean Med Sci; 2024 Aug; 39(31):e222. PubMed ID: 39137809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triptan use in Italy: Insights from administrative databases.
    Da Cas R; Nigro A; Terrazzino S; Sances G; Viana M; Tassorelli C; Nappi G; Cargnin S; Pisterna A; Traversa G; Genazzani AA
    Cephalalgia; 2015 Jun; 35(7):619-26. PubMed ID: 25246521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identifying the factors underlying discontinuation of triptans.
    Wells RE; Markowitz SY; Baron EP; Hentz JG; Kalidas K; Mathew PG; Halker R; Dodick DW; Schwedt TJ
    Headache; 2014 Feb; 54(2):278-89. PubMed ID: 24001117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health care resource utilization following initiation of a triptan: a retrospective claims analysis.
    Messali A; Owens G; Bloudek L; Kori S; Cole A; Chia J
    J Manag Care Spec Pharm; 2014 Apr; 20(4):368-75. PubMed ID: 24684641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Twenty-five years of triptans - a nationwide population study.
    Davidsson OB; Olofsson IA; Kogelman LJ; Andersen MA; Rostgaard K; Hjalgrim H; Olesen J; Hansen TF
    Cephalalgia; 2021 Jul; 41(8):894-904. PubMed ID: 33583217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of Acute Myocardial Infarction, Heart Failure, and Death in Migraine Patients Treated with Triptans.
    Ghanshani S; Chen C; Lin B; Duan L; Shen YA; Lee MS
    Headache; 2020 Nov; 60(10):2166-2175. PubMed ID: 33017476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perinatal use of triptans and other drugs for migraine-A nationwide drug utilization study.
    Tauqeer F; Wood M; Hjorth S; Lupattelli A; Nordeng H
    PLoS One; 2021; 16(8):e0256214. PubMed ID: 34424941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of ischemic complications related to the intensity of triptan and ergotamine use.
    Wammes-van der Heijden EA; Rahimtoola H; Leufkens HG; Tijssen CC; Egberts AC
    Neurology; 2006 Oct; 67(7):1128-34. PubMed ID: 17030745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coprescription of triptans with potentially interacting medications: a cohort study involving 240,268 patients.
    Tepper S; Allen C; Sanders D; Greene A; Boccuzzi S
    Headache; 2003 Jan; 43(1):44-8. PubMed ID: 12864757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.